David Llobet‐Navàs

7.0k total citations · 2 hit papers
46 papers, 3.4k citations indexed

About

David Llobet‐Navàs is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, David Llobet‐Navàs has authored 46 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 18 papers in Cancer Research and 13 papers in Oncology. Recurrent topics in David Llobet‐Navàs's work include MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (8 papers) and Cell death mechanisms and regulation (5 papers). David Llobet‐Navàs is often cited by papers focused on MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (8 papers) and Cell death mechanisms and regulation (5 papers). David Llobet‐Navàs collaborates with scholars based in Spain, United States and United Kingdom. David Llobet‐Navàs's co-authors include Xavier Matías‐Guiu, Xavier Dolcet, Judit Pallarés, Andrea Califano, José Silva, Pavel Sumazin, Hua‐Sheng Chiu, Xuerui Yang, Archana Iyer and Wei‐Jen Chung and has published in prestigious journals such as Cell, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

David Llobet‐Navàs

43 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

NF-kB in development and progression of human cancer

2005 910 citations Xavier Dolcet, David Llobet‐Navàs et al. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin profile →
An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma

2011 580 citations Pavel Sumazin, Xuerui Yang et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Llobet‐Navàs Spain	27	2.4k	1.4k	620	466	254	46	3.4k
Judit Pallarés Spain	21	1.3k 0.5×	590 0.4×	516 0.8×	298 0.6×	274 1.1×	31	2.2k
Ming-Derg Lai Taiwan	32	1.5k 0.6×	532 0.4×	519 0.8×	564 1.2×	118 0.5×	70	2.8k
Tim H.‐M. Huang United States	37	3.5k 1.5×	1.0k 0.7×	852 1.4×	322 0.7×	220 0.9×	118	4.7k
Nayiyuan Wu China	24	1.7k 0.7×	1.1k 0.8×	742 1.2×	426 0.9×	92 0.4×	84	2.9k
Jichun Zhou China	30	2.9k 1.2×	2.0k 1.4×	685 1.1×	448 1.0×	166 0.7×	79	4.5k
Insoo Bae United States	32	2.5k 1.0×	688 0.5×	1.4k 2.2×	261 0.6×	187 0.7×	61	3.5k
Ping Ji United States	31	4.0k 1.7×	2.6k 1.9×	754 1.2×	321 0.7×	175 0.7×	95	5.1k
Patrick Viatour United States	21	1.9k 0.8×	1.0k 0.7×	709 1.1×	720 1.5×	162 0.6×	27	3.2k
Ryan J.O. Dowling Canada	19	3.9k 1.6×	1.1k 0.8×	1.6k 2.6×	362 0.8×	177 0.7×	29	4.8k
Liang Zhao China	38	2.4k 1.0×	1.4k 1.0×	709 1.1×	402 0.9×	324 1.3×	166	3.7k

Countries citing papers authored by David Llobet‐Navàs

Since Specialization

Citations

This map shows the geographic impact of David Llobet‐Navàs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Llobet‐Navàs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Llobet‐Navàs more than expected).

Fields of papers citing papers by David Llobet‐Navàs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Llobet‐Navàs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Llobet‐Navàs. The network helps show where David Llobet‐Navàs may publish in the future.

Co-authorship network of co-authors of David Llobet‐Navàs

This figure shows the co-authorship network connecting the top 25 collaborators of David Llobet‐Navàs. A scholar is included among the top collaborators of David Llobet‐Navàs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Llobet‐Navàs. David Llobet‐Navàs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eritja, Núria, et al.. (2025). Dysregulated autophagy in endometriosis: molecular mechanisms, controversies, and clinical implications. Reproductive Biology and Endocrinology. 24(1). 8–8.

Bonifaci, Núria, Raúl Navaridas, Joaquim Egea, et al.. (2025). Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503. Cell Death and Disease. 16(1). 705–705.

Veiga, Sónia R., Jèssica Latorre, José María Moreno‐Navarrete, et al.. (2022). A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis. JCI Insight. 7(14). 6 indexed citations

Molina-Crespo, Ángela, Carmen Ramos, Lidia Martínez, et al.. (2022). Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation. Journal of Experimental & Clinical Cancer Research. 41(1). 285–285. 26 indexed citations

Jiménez, Carlos, Mariona Nadal‐Ribelles, Laura Devis, et al.. (2022). Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program. Molecular Cancer. 21(1). 175–175. 7 indexed citations

Rodríguez‐Barrueco, Ruth, Erin A. Nekritz, François Bertucci, et al.. (2017). miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes & Development. 31(6). 553–566. 71 indexed citations

Eritja, Núria, María Dosil Santamaría, Cristina Mirantes, et al.. (2017). A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium. Cell Death and Differentiation. 24(8). 1443–1458. 23 indexed citations

Putcha, Preeti, Jiyang Yu, Ruth Rodríguez‐Barrueco, et al.. (2015). HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research. 17(1). 149–149. 38 indexed citations

Herranz, Daniel, Alberto Ambesi‐Impiombato, Teresa Palomero, et al.. (2014). A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine. 20(10). 1130–1137. 303 indexed citations

10.

Eritja, Núria, et al.. (2012). ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNFα and IL1α in lumen formation and maintenance.. Journal of Cell Science. 125(Pt 8). 1929–44. 11 indexed citations

11.

Sumazin, Pavel, Xuerui Yang, Hua‐Sheng Chiu, et al.. (2011). An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma. Cell. 147(2). 370–381. 580 indexed citations breakdown →

12.

Montserrat, Núria, Anna Mozos, David Llobet‐Navàs, et al.. (2011). Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Human Pathology. 43(5). 632–643. 67 indexed citations

13.

Eritja, Núria, et al.. (2010). A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. American Journal Of Pathology. 176(6). 2722–2731. 39 indexed citations

14.

Llecha, Núria, Marı́a Santacana, Sónia Gatius, et al.. (2009). DcR1 expression in endometrial carcinomas. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 456(1). 39–44. 13 indexed citations

15.

Pallarés, Judit, Xavier Dolcet, David Llobet‐Navàs, et al.. (2008). Nuclear factor–κB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Human Pathology. 39(7). 994–1001. 26 indexed citations

16.

Pallarés, Judit, David Llobet‐Navàs, Marı́a Santacana, et al.. (2008). CK2β Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. American Journal Of Pathology. 174(1). 287–296. 30 indexed citations

17.

Dolcet, Xavier, David Llobet‐Navàs, Mario Encinas, et al.. (2006). Proteasome Inhibitors Induce Death but Activate NF-κB on Endometrial Carcinoma Cell Lines and Primary Culture Explants. Journal of Biological Chemistry. 281(31). 22118–22130. 90 indexed citations

18.

Pallarés, Judit, José‐Luis Martínez‐Guitarte, Xavier Dolcet, et al.. (2005). Survivin Expression in Endometrial Carcinoma:. International Journal of Gynecological Pathology. 24(3). 247–253. 51 indexed citations

19.

Dolcet, Xavier, David Llobet‐Navàs, Judit Pallarés, et al.. (2005). FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Laboratory Investigation. 85(7). 885–894. 54 indexed citations

20.

Pallarés, Judit, José‐Luis Martínez‐Guitarte, Xavier Dolcet, et al.. (2004). Abnormalities in the NF‐κB family and related proteins in endometrial carcinoma. The Journal of Pathology. 204(5). 569–577. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact